GlassScriptPhysician profile
Stephen M Menitove
NPI 1497740815
$2,961.43
in general payments reported to CMS, 2019-2025
24 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,265 · 2020: $420 · 2023: $28.91 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,168.13 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $263.21 | 2019-2025 | Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.76 | 2019-2025 | |
| Sanofi Pasteur INC. | $137.63 | 2020 | |
| Insmed, INC. | $136.74 | 2019-2020 | |
| Mylan Specialty L.P. | $123.68 | 2019-2020 | |
| Pfizer INC. | $122.97 | 2019-2025 | |
| Genzyme Corporation | $119.85 | 2019-2020 | |
| Genentech USA, INC. | $95.24 | 2019-2020 | |
| Electromed, INC. | $95.17 | 2019-2025 | Smartvest |
| Philips North America LLC | $80.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $69.66 | 2019-2020 | |
| Circassia INC. | $60.60 | 2019-2020 | |
| Grifols USA, LLC | $53.49 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $35.35 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.12 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $28.64 | 2025 | Lumryz |
| Verona Pharma, INC. | $27.67 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $24.16 | 2019-2020 | |
| Amgen INC. | $21.43 | 2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $18.40 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.19 | 2019 | |
| Amarin Pharma, INC. | $15.29 | 2019 | |
| Merck Sharp & Dohme LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Menitove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.